November 2017: Eris Lifesciences Ltd (Eris) acquired the Indian branded formulations business of Strides Shasun Ltd (Strides) for an aggregate cash consideration of INR 500 crores. With this acquisition, Eris acquired the marketing and distribution rights for India for 130+ brands in the Neurology, Psychiatry, Nutraceuticals and Women Healthcare therapy areas. The Indian branded formulations business being divested by Strides had sales of INR 181 crores for FY 2017.
October 2017 UTH is largely engaged in the segments of Obesity, Diabetes, Gestational diabetes mellitus, Maternal nutrition, and Cardio-vascular diseases. The acquisition provides Eris with a portfolio of products that complement its other offerings.
In December 2016, We have entered into a distribution agreement with India Medtronic Private Limited for the distribution, marketing and promotion of the ‘i-Port Advance’ injection port which requires less injections than standard insulin delivery methods.
Life with Insulin is the ultimate stage of any diabetes patient which compels a patient to prick himself before every meal. Apart from physical impact of prick, it also poses emotional challenge to individual, resulting in fear, anxiety and cognitive stress. Our compassion towards diabetes patients motivated us to launch the breakthrough iPort advance- an Insulin delivery device which takes the pricks for the patients. This novel technology helps a diabetes patient to live a normal person’s life with almost 93% less pricks.
November 2016 Eris acquires majority stake in Kinedex Healthcare Private Limited
July 2016 Eris acquires trademarks in relation to 40 brands, from Amay Pharma